Analyst Price Target is $8.40
▲ +1,131.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Passage Bio in the last 3 months. The average price target is $8.40, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 1,131.67% upside from the last price of $0.68.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Passage Bio. This Buy consensus rating has held steady for over two years.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.